N/A N=15 Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum
Pectus Excavatum
Primary: Number of Participants With Adverse Reactions — 13; 15; 14; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus
Humerus Fracture Metastatic Bone Disease
Primary: Change in Pain — -52.7 units on a scale — p=0.615
N/A N=15 Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material
Facial Injuries
Primary: Soft Tissue Volume After Autologous Fat Grafting Using CT Scans. — 11.4; 7.4; 6.5 milliliters
Phase 2 N=20 Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Progression-free Survival. — 7.8 Months
N/A N=6 Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Number of Adverse Events From 2 Weeks Post-op Until the End of the Study — 34 total number of AEs
N/A N=150 Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache
Cluster Headache
Primary: Number of Participants With Repsonse to Treatment — 14; 16; 57; 44 Participants
Phase 2 N=30 Tau Imaging of Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr
Phase 3 N=517 Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Hypercholesterolaemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -51.8; -3.9; -48.2; 0.8 percent change — p=<0.0001
Phase 1 N=32 Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 0; 2; 0; 1 participants
Phase 4 N=25 EASY: Extended Access to Sollpura Over Years
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety, as Measured by Number of Participants With Adverse Events Including Clinical or Laboratory Abnormalities — 25; 9 Participants
Phase 3 N=143 Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
Urinary Incontinence, Stress
Primary: Percentage of Participants With Response (Based on Stress IEF, or In-office Pad Weight Test, or 24-hour Pad Weight Test) at 12 Months — 82; 90 Percentage of subjects
N/A N=25 Four Way Crossover Closed Loop With Exercise Detection
Type 1 Diabetes
Primary: Percent of Time With Sensed Glucose < 3.9 mmol/L — 1.8; 1.2; 2.7; 3.0 percentage of 84 hours
Phase 2 N=41 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Proportion of Confirmed Responses Defined to be a CR or PR Noted as the Objective Status — 0.21 proportion of CR or PR patients
N/A N=165 Atrium iCAST Iliac Stent Pivotal Study
Peripheral Vascular Disease
Primary: Percentage of ITT Population Experiencing Death Within 30 Days, Target Site Revascularization or Restenosis — 8.1 Percentage of subjects — p=0.005
Phase 3 N=140 Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
Asthma
Primary: Percent Change From Baseline in the Final Daily, Average, OCS Dose at Week 40 While Not Losing Asthma Control. — -37.62; -29.85 Percent change from baseline — p=0.271